Bladder Cancer
Transformative or transitional? Deciphering the role of NIAGARA in shaping future practice.
December 25, 2024
Exploring the Immunoresponse in Bladder Cancer Immunotherapy.
December 25, 2024
Reflections on the AMBASSADOR trial: The role of adjuvant pembrolizumab in muscle-invasive urothelial carcinoma.
December 24, 2024
Evaluation of Gemcitabine and Carboplatin Dosing in Patients With Cisplatin-Ineligible Metastatic Urothelial Carcinoma.
December 24, 2024
Prospective Analysis of Confocal Laser Endomicroscopy for Assessment of the Resection Bed for Bladder Tumor.
December 23, 2024
FDA Approval Summary: Nadofaragene firadenovec-vncg for bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer.
December 23, 2024
Low-cost and label-free blue light cystoscopy through digital staining of white light cystoscopy videos.
December 20, 2024
Prognostic Value of a B Cell Exhaustion Gene Signature in Bladder Cancer - Expert Commentary
December 19, 2024
Retrospective analysis of partial cystectomy in patients with muscle-invasive urothelial carcinoma: A German single-center experience.
December 19, 2024
A multimodal deep-learning model based on multichannel CT radiomics for predicting pathological grade of bladder cancer.
December 19, 2024
Developing and experimental validating a B cell exhaustion-related gene signature to assess prognosis and immunotherapeutic response in bladder cancer.
December 19, 2024
Phase II Trial of Risk-Enabled Therapy After Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer (RETAIN 1).
December 18, 2024
The Role of Antibody-Drug Conjugates in Urothelial Cancer: A Review of Recent Advances in the Treatment of Locally Advanced and Metastatic Urothelial Cancer.
December 18, 2024
Impact of smoking exposure on disease progression in high risk and very high-risk nonmuscle invasive bladder cancer patients undergoing BCG therapy.
December 17, 2024